AstraZeneca announces EU approval of Imfinzi for muscle-invasive bladder cancer, showing significant survival benefits and addressing critical treatment needs.
Discover key findings from AstraZeneca's 6-K filing on Imfinzi, highlighting significant advancements in treating high-risk non-muscle-invasive bladder cancer through the POTOMAC trial.
Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.
Explore AstraZeneca's 6-K filing detailing Imfinzi's Phase III MATTERHORN trial results, showing significant improvements in event-free survival for gastric cancer patients.
AstraZeneca's Imfinzi receives EU approval as the first immunotherapy for LS-SCLC, showing significant survival benefits. This landmark decision highlights advancements in cancer care.
Discover AstraZeneca's groundbreaking approval of Imfinzi for muscle-invasive bladder cancer, backed by clinical trials showing improved survival rates and reduced recurrence.
Explore Estrella Immunopharma's February 2025 8-K filing, detailing stock info, warrants, and key financial insights for investors.
Explore Citius Oncology's Q4 2024 financial performance, including a $6.6M net loss, cash struggles, and reliance on parent funding, all crucial for investor decisions.
Explore Sonnet BioTherapeutics' Q4 2024 financials, highlighting cash position, R&D losses, and strategic partnerships in oncology. Key insights and investment recommendations included.
Explore Replimune Group, Inc.'s Q4 2024 financial report. Key insights on losses, cash management, and clinical trial outcomes suggest a 'Hold' stock recommendation.
Explore the latest 8-K report from Vaxart, Inc. (Ticker: VXRT) detailing significant corporate events as of December 20, 2024. Stay informed on their NASDAQ activities.
Discover key insights from Portage Biotech Inc.'s Form 6-K filed on Dec 17, 2024, detailing their LOI with Immunova for iOx Therapeutics acquisition, signaling potential growth.